Tags

Type your tag names separated by a space and hit enter

Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Ther Apher Dial. 2008 Oct; 12 Suppl 1:S27-33.TA

Abstract

The management of hemodialysis patients with chronic kidney disease-mineral bone disorder includes treatment to control levels of calcium, phosphorus and parathyroid hormone, so as to prevent bone and soft-tissue complications. Recently, pleiotropic effects of active vitamin D have attracted much attention, and its effect on outcome has also gained recognition. However, administration of active vitamin D may cause hypercalcemia and hyperphosphatemia. Now, the use of a novel class of drugs, cinacalcet hydrochloride, has been proposed as a strategy to reduce parathyroid hormone secretion, while decreasing levels of serum calcium, phosphorus, and calcium x phosphorus products. Among subjects with secondary hyperparathyroidism undergoing hemodialysis, combined therapy with cinacalcet and vitamin D sterols improved achievement of the biochemical targets for chronic kidney disease-mineral bone disorder recommended by the guidelines.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Tahara H
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-cho, Abeno-ku, Osaka, Japan. hidekit@ka2.so-net.ne.jp

MeSH

CalciumChronic Kidney Disease-Mineral and Bone DisorderCinacalcetDrug Therapy, CombinationHumansHyperparathyroidism, SecondaryKidney Failure, ChronicNaphthalenesParathyroid HormonePhosphorusPractice Guidelines as TopicRenal DialysisTreatment OutcomeVitamin D

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19032524

Citation

Tahara, Hideki. "Role of Cinacalcet in Management of Mineral Bone Disorder in Chronic Kidney Disease (control of Calcium, Phosphorus and Parathyroid Hormone)." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 12 Suppl 1, 2008, pp. S27-33.
Tahara H. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone). Ther Apher Dial. 2008;12 Suppl 1:S27-33.
Tahara, H. (2008). Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone). Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 12 Suppl 1, S27-33. https://doi.org/10.1111/j.1744-9987.2008.00628.x
Tahara H. Role of Cinacalcet in Management of Mineral Bone Disorder in Chronic Kidney Disease (control of Calcium, Phosphorus and Parathyroid Hormone). Ther Apher Dial. 2008;12 Suppl 1:S27-33. PubMed PMID: 19032524.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone). A1 - Tahara,Hideki, PY - 2008/11/27/pubmed PY - 2009/2/20/medline PY - 2008/11/27/entrez SP - S27 EP - 33 JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JO - Ther Apher Dial VL - 12 Suppl 1 N2 - The management of hemodialysis patients with chronic kidney disease-mineral bone disorder includes treatment to control levels of calcium, phosphorus and parathyroid hormone, so as to prevent bone and soft-tissue complications. Recently, pleiotropic effects of active vitamin D have attracted much attention, and its effect on outcome has also gained recognition. However, administration of active vitamin D may cause hypercalcemia and hyperphosphatemia. Now, the use of a novel class of drugs, cinacalcet hydrochloride, has been proposed as a strategy to reduce parathyroid hormone secretion, while decreasing levels of serum calcium, phosphorus, and calcium x phosphorus products. Among subjects with secondary hyperparathyroidism undergoing hemodialysis, combined therapy with cinacalcet and vitamin D sterols improved achievement of the biochemical targets for chronic kidney disease-mineral bone disorder recommended by the guidelines. SN - 1744-9987 UR - https://www.unboundmedicine.com/medline/citation/19032524/Role_of_cinacalcet_in_management_of_mineral_bone_disorder_in_chronic_kidney_disease__control_of_calcium_phosphorus_and_parathyroid_hormone__ L2 - https://doi.org/10.1111/j.1744-9987.2008.00628.x DB - PRIME DP - Unbound Medicine ER -